Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Inventiva shares traded unusually heavily, with about 872,731 shares changing hands—just below the prior session’s volume—while the stock edged up to $3.175.
• Analysts remain broadly bullish: Inventiva has an average “Buy” rating and a consensus price target of $15.86, though ratings range from “Strong Buy” to “Sell.”
• The clinical-stage biotech reported a quarterly loss of $0.14 per share on $0.75 million in revenue. Its lead candidate, lanifibranor, is being tested in the Phase 3 NATiV3 trial for MASH, while institutional investors own 19.06% of the stock.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw unusually-high trading volume on Monday. Approximately 872,731 shares traded hands during mid-day trading, a decline of 2% from the previous session's volume of 893,689 shares. The stock last traded at $3.1750 and had previously closed at $3.16.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on IVA shares. Wall Street Zen upgraded Inventiva from a "sell" rating to a "hold" rating in a research report on Saturday, October 3rd. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Guggenheim raised their price target on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Truist Financial raised their price objective on Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an "overweight" rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $15.86.

Inventiva Stock Performance

The business has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.56.

Inventiva (NASDAQ:IVA - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million during the quarter. As a group, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of Inventiva

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Platt Investment Counsel LLC bought a new position in Inventiva in the third quarter worth approximately $45,000. Engineers Gate Manager LP lifted its position in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after buying an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Inventiva during the fourth quarter valued at $603,000. Seven Fleet Capital Management LP purchased a new position in shares of Inventiva in the 1st quarter worth approximately $1,111,000. Finally, Eventide Asset Management LLC bought a new position in Inventiva during the fourth quarter valued at $1,155,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.